(Q37514625)

20 August 2017

1 reference

title

Invasive candidiasis: an overview from Taiwan (English)

1 reference

20 August 2017

1 reference

1 reference

2

Po-Ren Hsueh

1 reference

20 August 2017

Sheng-Yuan Ruan

1

1 reference

20 August 2017

language of work or name

1 reference

1 June 2009

1 reference

20 August 2017

number of pages

9

1 reference

Journal of the Formosan Medical Association

inferred from page(s)

published in

1 reference

20 August 2017

volume

108

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

443-451

1 reference

Secular Trends in the Epidemiology of Nosocomial Fungal Infections at a Teaching Hospital in Taiwan, 1981 to 1993

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Antimicrobial drug resistance in pathogens causing nosocomial infections at a university hospital in Taiwan, 1981-1999

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Nosocomial bloodstream infections in children and adolescents in southern Israel: a 10-year prospective study (1992-2001)

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Epidemiology of nosocomial bloodstream infections in Belgium, 1992-1996

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Effects of nosocomial candidemia on outcomes of critically ill patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Epidemiology of invasive candidiasis: a persistent public health problem

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Candidemia in intensive care unit patients: Risk factors for mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Candida glabrata fungaemia in intensive care units

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Predictors of adverse outcome in cancer patients with candidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion test

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

The epidemiology of hematogenous candidiasis caused by different Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Epidemiological trends in nosocomial candidemia in intensive care

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Trends in the epidemiology of Candida bloodstream infections in Northern Ireland between January 1984 and December 2000

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

A multicenter, randomized trial of prophylactic fluconazole in preterm neonates.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

The discovery and profile of fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Guidelines for treatment of candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Mechanism of fluconazole resistance in Candida krusei

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

In vitro activity of voriconazole against Candida species isolated in Taiwan

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Antifungal susceptibility testing: practical aspects and current challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2809%2960091-7

7 January 2021

10.1016/S0929-6646(09)60091-7

Identifiers

DOI

1 reference

20 August 2017

1 reference